Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 16 of 16 results for candidiasis

  1. Urinary tract infection (recurrent). Patient decision aid on reducing the chance of recurrent urinary tract infection (UTI) in postmenopausal women

    not everyone gets them. These include feeling or being sick, diarrhoea and thrush. About 10 to 20 women in 100 get these (so 80 to 90...

  2. Urinary tract infection (recurrent). Patient decision aid on reducing the chance of recurrent urinary tract infection (UTI) in premenopausal women who are not pregnant

    not everyone gets them. These include feeling or being sick, diarrhoea and thrush. About 10 to 20 women in 100 get these (so 80 to 90 do...

  3. Urinary tract infection (lower). Patient decision aid on cystitis: taking an antibiotic

    nitrofurantoin (this is harmless) : diarrhoea : feeling sick or being sick : thrush : a rash. Rarely, antibiotics can cause more serious...

  4. Antenatal care (NG201)

    This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support. We have also published a guideline on postnatal care , which covers the topics of emotional attachment and baby feeding.

  5. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (DG20)

    Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi

  6. HIV testing: encouraging uptake (QS157)

    This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.

  7. Fungitell for antifungal treatment stratification (MIB118)

    NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .

  8. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  9. Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)

    This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.

  10. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

    Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.

  11. Antimicrobial stewardship (QS121)

    This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.

  12. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

  13. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

  14. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in adults and children aged 12 and over.

  15. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in children under 12.

  16. Rezafungin for untreated invasive candidiasis TS ID 10768

      Status ...